ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 40; no. 3; pp. 301 - 307
• Main Authors: Pallis, A.G., Mavroudis, D., Androulakis, N., Souglakos, J., Kouroussis, C., Bozionelou, V., Vlachonikolis, I.G., Georgoulias, V.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.06.2003; Elsevier Science
• Subjects: Administration, Oral; Adult; Advanced NSCLC; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacology; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Epidermal Growth Factor - antagonists & inhibitors; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Medical sciences; Middle Aged; Pneumology; Protein-Tyrosine Kinases - antagonists & inhibitors; Quinazolines - administration & dosage; Quinazolines - adverse effects; Quinazolines - pharmacology; Salvage Therapy; Treatment Outcome; Tumors of the respiratory system and mediastinum; ZD1839; Advanced NSCLC; ZD1839; Antineoplastic agent; Human; Lung disease; Respiratory disease; Enzyme; Transferases; Lung cancer; Oral administration; Malignant tumor; non-small cell lung carcinoma; Bronchopulmonary; Chemotherapy; Growth factor receptor; Epidermal growth factor; Treatment; Bronchus disease; Inhibitor; EC 2.7.1.112; Protein-tyrosine kinase; Non small cell carcinoma

Objective: We evaluated the efficacy and tolerability of the orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) ZD1839 in patients with pretreated advanced non-small cell lung cancer (NSCLC) participating in a compassionate use program. Patients and method...